ABL1 and acute lymphoblastic leukemia: Most CML patients can expect to live a near-normal lifespan owing to targeted therapy with tyrosine kinase inhibitors (TKIs), whereas the survival of BCR-ABL1 lymphoblastic leukemia patients remains dismal despite TKI intervention1,2.